Substance / Medication

Interferon alfacon-1

Overview

Active Ingredient
interferon alfacon-1
RxNorm CUI
59744

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

190 trials linked to this intervention

190
Total Trials
21
Recruiting
76
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters.
Gowen Brian B, Smee Donald F, Wong Min-Hui et al. · Antivir Chem Chemother · 2006
PMID: 17066896Observational
Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids.
Ward Sarah E, Loutfy Mona R, Blatt Lawrence M et al. · Antivir Ther · 2005
PMID: 15865221Observational
Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin.
Kleppinger Erika L, Ragan Addison P · Am J Health Syst Pharm · 2009
PMID: 19233994Case Report
Cutaneous mucinosis and skin necrosis complicates interferon alfacon-1 (consensus interferon) treatment of chronic hepatitis C.
Siewert E, Weyers W, Dietrich C G et al. · Eur J Med Res · 2005
PMID: 15817424Case Report
Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1.
Dimitroulopoulos D, Dourakis S P, Xinopoulos D et al. · J Viral Hepat · 2004
PMID: 15357656Case Report
Maillard reaction products in the Escherichia coli-derived therapeutic protein interferon alfacon-1.
Mironova Roumyana, Sredovska Angelina, Ivanov Ivan et al. · Ann N Y Acad Sci · 2008
PMID: 18079487Other
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon Bruce R, Shiffman Mitchell L, Mendes Flavia et al. · Hepatology · 2009
PMID: 19291790Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Interferon alfacon-1 (substance)
SNOMED CT
108745009
UMLS CUI
C0164613
RxNorm CUI
59744

Clinical Data

This intervention maps to 26 entities in the Healos knowledge graph.

20
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
190
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.

Interferon alfacon-1 — Conditions, Biomarkers & Specialists | Healos | Ltrl